Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced successful new trial data from the long-term recurrent injection group from the Phase III study for fexapotide. It is the firm’s lead compound in late phase advancement for enlarged prostate and for localized prostate cancer.

The objective of the trial was to decide the clinical benefit and safety fexapotide can offer to men who were administered a second injection of fexapotide for BPH. In the latest trial long-term results were decided in 344 subjects who were offered a single repeat fexapotide regimen after preliminary blinded treatment with placebo or fexapotide.

Subjects were followed for an average 4.2 years after preliminary treatment. All regimen failures were covered in the assessment. Data have now proven that there had been long-term statistically considerable symptomatic improvement compared to Phase III subjects who obtained placebo alone. Repeat injection was established to be safe with no considerable drug related side effects or toxicities found in the trial.

The experts speak

Dr. Paul Averback MD, who is the CEO of Nymox said that this trial data in reinjected patients show that fexapotide results in clinically important long-term symptomatic enhancements in BPH subjects. This is achieved with minimal treatment, and in absence of the bothersome and worrisome toxicities of conservative BPH regimens such as increased cancer risk and retrograde ejaculation.

The earlier announced Phase III trials have proven that fexapotide minimizes the long-term requirement for surgery by nearly 82-95% as against approved conservative BPH regimen. Data suggests that fexapotide shows considerable effectiveness against prostate cancer when used as a therapeutic. In addition, it has shown to mitigate the prostate cancer risk when fexapotide is utilized to cure BPH. This is against some conventional BPH regimen in routine clinical application which on contrary intensifies prostate cancer risk.

Nymox’s lead candidate fexapotide has been in advancement for more than a decade. It has been assessed by expert clinical study investigative teams in more than 70 eminent clinical trial centers in the U.S. The company expects to release further results and analyses when available in the imminent future. It will issue the data of the fexapotide clinical studies in peer review medical journals and in presentations at urological and medical meetings.

Previous articleGevo, Inc. (NASDAQ:GEVO) Completes Production Of First Cellulosic Renewable Jet Fuel
Next articleVPR Brands LP (OTCMKTS:VPRB) Acquires Wholesale Business Assets Of Vapor Corp (OTCMKTS:VPCO)
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.